title: PHARMAC's response on gemcitabine and transparency.
authors.forename: Steffan
authors.initials: S
authors.lastname: Crausaz
authors.forename: Scott
authors.initials: S
authors.lastname: Metcalfe
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000191:economics / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D017277:Drug Approval / Q000191:economics / Q000379:methods*; D006801:Humans; D009313:National Health Programs / Q000458:organization & administration; D009520:New Zealand; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine